While I think revenues are still snowballing as word spreads...

While I think revenues are still snowballing as word spreads among clinicians, I would say its still relatively small and maybe only 5% or less of the surgeons who could potentially use it have even heard of it. We got abnormally high growth last year, probably because of conflict in Ukraine and the Middle East so growth this year might look like its slowed but in truth hasn't over a longer time scale. In fact at $125m FY, growth would still be accelerating. And we still have the BARDA and chronic wound trial results to look forward to along with orders in India.

All in My humble opinion of course